Biosimilars in 3D: Definition, development and differentiation

Bioengineered

Volumn 4, Issue 4, 2013, Pages 203-206

  Abraham, Ivo ^a,b   Sun, Diana ^a   Bagalagel, Alaa ^a,c   Altyar, Ahmed ^a,c   Mohammed, Abdulaziz ^a,c   Tharmarajah, Soba ^a,b   MacDonald, Karen ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b Matrix45   (United States)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Biopharmaceuticals; Biosimilars; Follow on biologics; Interchangeable; Regulatory; Substitution

Indexed keywords

BIOSIMILAR AGENT; GENERIC DRUG; RECOMBINANT DNA; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ALLERGY; ANAPHYLAXIS; ARTICLE; BIOEQUIVALENCE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MANUFACTURE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; IMMUNOGENICITY; PHARMACOEPIDEMIOLOGY; PHYSICAL CHEMISTRY; STRUCTURE ANALYSIS;

BIOPHARMACEUTICALS; BIOSIMILARS; FOLLOW-ON BIOLOGICS; INTERCHANGEABLE; REGULATORY; SUBSTITUTION;

BIOSIMILAR PHARMACEUTICALS; DRUG DISCOVERY; HUMANS;

EID: 84883257421     PISSN: 19491018     EISSN: 19491026     Source Type: Journal    
DOI: 10.4161/bioe.25067     Document Type: Article

References (27)

1. Beck A, Sanglier-Cianférani S, Van Dorsselaer A. Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. Anal Chem 2012; 84:4637-46; PMID:22510259; http://dx.doi.org/10.1021/ac3002885
2. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol 2008; 19:411-9; PMID:17872902; http://dx.doi.org/10.1093/annonc/mdm345
3. European public assessment reports [Internet]. London (UK): European Medicines Agency: c1995-2013 [cited 27 March 2013]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d125.
4. Abraham I, MacDonald K. Clinical safety of bio-similar recombinant human erythropoietins. Expert Opin Drug Saf 2012; 11:819-40; PMID:22880621; http://dx.doi.org/10.1517/14740338.2012.712681
5. Abraham I, MacDonald K. Clinical efficacy and safety of HX575, a biosimilar recombinant human eryth-ropoietin, in the management of anemia. Biosimilars 2012; 2:13-25; http://dx.doi.org/10.2147/BS.S28707
6. Gesualdo L, London G, Turner M, Lee C, Macdonald K, Goldsmith D, et al. A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients: background and methodology of the MONITOR-CKD5 study. Intern Emerg Med 2011; PMID:21590439; http://dx.doi.org/10.1007/s11739-011-0622-7
7. Bagalagel A, Mohammed A, MacDonald K, Abraham I. Clinical efficacy and safety of SB309, a biosimilar recombinant human erythropoietin, in the management of anemia. Biosimilars, In press.
8. Mohammed A, Bagalagel A, MacDonald K, Abraham I. Clinical efficacy and safety of XM01, a biosimilar recombinant human erythropoietin, in the management of anemia. Biosimilars, In press.
9. Abraham I, Tharmarajah S, MacDonald K. Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors. Expert Opin Drug Saf 2013; 12:235-46; PMID:23419039 http://dx.doi.org/10.1517/14740338.2013.770472
10. Gascón P, Aapro M, Ludwig H, Rosencher N, Boccadoro M, Turner M, et al. Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments. Crit Rev Oncol Hematol 2011; 77:198-200; PMID:21377576; http://dx.doi.org/10.1016/j.crit-revonc.2011.01.006
11. Gascón P, Aapro M, Ludwig H, Rosencher N, Turner M, Song M, et al. Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim. Crit Rev Oncol Hematol 2011; 77:184-97; PMID:20189821; http://dx.doi.org/10.1016/j.critrevonc.2010.01.014
12. Barosi G, Bosi A, Abbracchio MP, Danesi R, Genazzani A, Corradini P, et al. Key concepts and critical issues on epoetin and filgrastim bio-similars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica 2011; 96:937-42; PMID:21719882; http://dx.doi.org/10.3324/haema-tol.2011.041210
13. Lonnemann G, Macdougall IC. Biosimilar epoetins in renal anaemia - current status and insights from European practice. Eur Nephrol 2011; 5:101-7
14. What are generic drugs? [Internet]. Silver Spring (MD): US Food and Drug Administration: c2009 [cited 27 March 2013]. Available from: http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingGenericDrugs/ucm144456.htm.
15. Generic medicines [Internet]. London (UK): European Medicines Agency: c1995-2013 [cited 27 March 2013]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_top-ics/document_listing/document_listing_000335. jsp&mid=WC0b01ac0580514d5c.
16. Biosimilars medicines [Internet]. London (UK): European Medicines Agency: c1995-2013 [cited 27 March 2013]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_top-ics/document_listing/document_listing_000318.jsp&mid=WC0b01ac0580281bf0.
17. FDA issues draft guidance on biosimilar product development. [Internet]. Silver Spring (MD): US Food and Drug Administration: c2012 [cited 27 March 2013]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm291232.htm.
18. Patient Protection and Affordable Care Act, as amended by the 111th Congress, H.R. 3590 [Internet]. Washington, DC: U.S. Government Printing Office: c2010 [cited 27 March 2013]. Available from: http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=111_cong_bills&docid=f:h3590enr.txt.pdf.
19. Schellekens H. Bioequivalence and the immunoge-nicity of biopharmaceuticals. Nat Rev Drug Discov 2002; 1:457-62; PMID:12119747; http://dx.doi.org/10.1038/nrd818
20. Roger SD. Biosimilars: how similar or dissimilar are they? Nephrology (Carlton) 2006; 11:341-6; PMID:16889575; http://dx.doi.org/10.1111/j.1440-1797.2006.00594.x
21. Dingermann T. Biosimilars - Business as usual oder eine neue pharmazeutische Herausforderung. Paper presented at: ABDA Wochenendworkshop Patient und Pharmazeutische Betreuung17-18 October 2009; Hannover, Germany.
22. Schellekens H. How similar do 'biosimilars' need to be? Nat Biotechnol 2004; 22:1357-9; PMID:15529154; http://dx.doi.org/10.1038/nbt1104-1357
23. Porter S. Human immune response to recombinant human proteins.JPharm Sci 2001; 90:1-11; PMID:11064373 http://dx.doi.org/10.1002/1520-017(200101)90:11::AID-JPS13.0.CO;2-K
24. Ryff JC, Schellekens H. Immunogenicity of rDNA-derived pharmaceuticals. Trends Pharmacol Sci 2002; 23:254-6; PMID:12084625; http://dx.doi.org/10.1016/S0165-6147(02)02024-2
25. Schellekens H. Biosimilar therapeutics-what do we need to consider? NDT Plus 2009; 2(Suppl_1):i27-36; PMID:19461855; http://dx.doi.org/10.1093/ndtplus/sfn177
26. Pendley C, Schantz A, Wagner C. Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 2003; 5:172-9; PMID:12772508
27. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. EMEA/CHMP/BMWP/42832/200522, February 2006 [Internet]. London (UK): European Medicines Agency: c2006 [cited 27 March 2013]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/ WC500003920.pdf.